Daiichi Sankyo Company, Limited

Sanford Burnham Prebys Medical Discovery Institute

Kyoto Pharmaceutical Industries, Ltd.

Sandford Burnham Prebys Medical Discovery Institute

Masaharu Inui

Anthony B Pinkerton

Yuko Yamamoto

Shojiro Miyazaki

Masanori Izumi

Kaori Soma

Keisuke Suzuki

Taeko Shinozaki

Takayuki Baba

Ken Ishii

Makoto Mori

Atsushi Aoyagi

Masaki Miyazaki

Rieko Takano

Kunihiko Fujii

Junya Kawai

Masamichi Kishida

Yukari Onishi

Yoshihiro Ogura

Yasunobu Kurosaki

Masafumi Ofuku

Shunsuke Takashima

Wakana Yokozeki

Masaya Fujii

Masafumi Ando

Teppei Fujimoto

Kazuya Otake

The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1): wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

Benzotriazole compound

The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof. 

Sulfonamide compounds

The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein Rrepresents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, Rand Rare the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, Rand Rare the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, Rrepresents a hydrogen atom or the like, each Rmay be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents &#x2014;CH&#x2550;, &#x2014;C(&#x2014;R)&#x2550;, or &#x2014;N&#x2550;, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.

Pyridine compounds

The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein Rrepresents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, Rand Rare the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, Rrepresents a hydrogen atom or the like, each Rmay be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents &#x2014;CH&#x2550;, &#x2014;C(&#x2014;R)&#x2550;, or &#x2014;N&#x2550;, and m represents 1 to 4, or a pharmacologically acceptable salt thereof. 

The present invention relates to a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof having an excellent effect of inhibiting 11&#x3b2;-hydroxysteroid dehydrogenase type 1: General formula (I) wherein Rrepresents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from substituent group A or a heterocyclic group that may be substituted with 1 to 4 group(s) independently selected from substituent group A; Rindependently represents a halogen atom or a C-Calkyl group; n represents an integer of 0 to 2; and substituent group A represents the group consisting of halogen atoms, C-Calkyl groups, and so forth.

Tetrahydrothiazepine derivative

Growing community of inventors

Tokyo, Japan

Masaharu Inui